Summary
7.73 -0.69(-8.19%)07/03/2024
Rigel Pharmaceuticals (RIGL)
Rigel Pharmaceuticals (RIGL)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -7.98 | 878.48 | 682.31 | 483.40 | 433.10 | 490.08 | 198.46 | -87.92 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 7.73 | |
| Open | 8.36 | |
| High | 8.41 | |
| Low | 7.68 | |
| Volume | 160,401 | |
| Change | -0.67 | |
| Change % | -7.98 | |
| Avg Volume (20 Days) | 1,023,906 | |
| Volume/Avg Volume (20 Days) Ratio | 0.16 | |
| 52 Week Range | 0.71 - 10.89 | |
| Price vs 52 Week High | -29.02% | |
| Price vs 52 Week Low | 988.73% | |
| Range | -7.54 | |
| Gap Up/Down | -0.11 | |
Fundamentals | ||
| Market Capitalization (Mln) | 136 | |
| EBIDTA | -14,551,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -0.1000 | |
| WallStreet Target Price | 4.53 | |
| Book Value | -0.1810 | |
| Earnings Per Share | -0.1100 | |
| EPS Estimate Current Quarter | -0.0300 | |
| EPS Estimate Next Quarter | -0.0200 | |
| EPS Estimate Current Year | -0.0700 | |
| EPS Estimate Next Year | 0.0600 | |
| Diluted EPS (TTM) | -0.1100 | |
| Revenues | ||
| Profit Marging | -0.1661 | |
| Operating Marging (TTM) | -0.2359 | |
| Return on asset (TTM) | -0.0791 | |
| Return on equity (TTM) | -6.9905 | |
| Revenue TTM | 119,246,000 | |
| Revenue per share TTM | 0.6840 | |
| Quarterly Revenue Growth (YOY) | 0.1330 | |
| Quarterly Earnings Growth (YOY) | -0.4790 | |
| Gross Profit (TTM) | 53,721,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 31.6366 | |
| Revenue Enterprise Value | 1.8170 | |
| EBITDA Enterprise Value | -12.5068 | |
| Shares | ||
| Shares Outstanding | 175,406,000 | |
| Shares Float | 146,985,088 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.03 | |
| Insider (%) | 2.11 | |
| Institutions (%) | 61.80 | |
06/25 08:00 EST - prnewswire.com
Rigel Announces Reverse Stock Split
SOUTH SAN FRANCISCO, Calif. , June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10 (the "Reverse Stock Split"), effective at 12:01 a.m.
Rigel Announces Reverse Stock Split
SOUTH SAN FRANCISCO, Calif. , June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10 (the "Reverse Stock Split"), effective at 12:01 a.m.
06/24 16:05 EST - prnewswire.com
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application
GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif. , June 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced the completion of the transfer to Rigel of the New Drug Application (NDA) for GAVRETO® (pralsetinib) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by a U.S. Food and Drug Administration (FDA) approved test and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application
GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif. , June 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced the completion of the transfer to Rigel of the New Drug Application (NDA) for GAVRETO® (pralsetinib) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by a U.S. Food and Drug Administration (FDA) approved test and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
06/17 09:36 EST - investorplace.com
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
Penny stocks sometimes get a bad rep due to their inherent risk. They are cheap but are considered highly volatile and have a low chance of providing substantial profit.
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
Penny stocks sometimes get a bad rep due to their inherent risk. They are cheap but are considered highly volatile and have a low chance of providing substantial profit.
06/14 03:05 EST - prnewswire.com
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
- Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML , including those receiving prior venetoclax - New data shows clinically meaningful effect of olutasidenib in patients with mIDH1 AML secondary to MPN and as bridge-to-transplant treatment in patients with R/R mIDH1 AML SOUTH SAN FRANCISCO, Calif. , June 14, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced one oral and four poster presentations at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain being held June 13-16, 2024, and online.
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
- Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML , including those receiving prior venetoclax - New data shows clinically meaningful effect of olutasidenib in patients with mIDH1 AML secondary to MPN and as bridge-to-transplant treatment in patients with R/R mIDH1 AML SOUTH SAN FRANCISCO, Calif. , June 14, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced one oral and four poster presentations at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain being held June 13-16, 2024, and online.
06/03 08:13 EST - prnewswire.com
Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting
- Long-term efficacy data from the registrational Phase 2 trial of REZLIDHIA ® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those receiving prior venetoclax - Data from a subgroup analyses of elderly R/R mIDH1 AML patients treated with olutasidenib shows consistent CR/CRh results - Overview of the Phase 1b trial of R289 in patients with lower-risk MDS SOUTH SAN FRANCISCO, Calif. , June 3, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the presentation of three posters at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL today and online.
Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting
- Long-term efficacy data from the registrational Phase 2 trial of REZLIDHIA ® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those receiving prior venetoclax - Data from a subgroup analyses of elderly R/R mIDH1 AML patients treated with olutasidenib shows consistent CR/CRh results - Overview of the Phase 1b trial of R289 in patients with lower-risk MDS SOUTH SAN FRANCISCO, Calif. , June 3, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the presentation of three posters at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL today and online.
05/30 08:05 EST - prnewswire.com
Rigel to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , May 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:30 am ET in New York, NY.
Rigel to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , May 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:30 am ET in New York, NY.
05/23 17:00 EST - prnewswire.com
Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
Oral presentation of f inal five-year results from the registrational Phase 2 trial in R/R mIDH1 AML patients reinforces REZLIDHIA® (olutasidenib) efficacy in heavily pretreated patients, including those receiving prior venetoclax Other key posters further support the efficacy of REZLIDHIA ® (olutasidenib) in elderly, transplant-eligible, and post-MPN patients with AML SOUTH SAN FRANCISCO, Calif. , May 23, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced upcoming presentations from their commercial and clinical-stage hematology and oncology portfolio at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2024 Hybrid Congress.
Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
Oral presentation of f inal five-year results from the registrational Phase 2 trial in R/R mIDH1 AML patients reinforces REZLIDHIA® (olutasidenib) efficacy in heavily pretreated patients, including those receiving prior venetoclax Other key posters further support the efficacy of REZLIDHIA ® (olutasidenib) in elderly, transplant-eligible, and post-MPN patients with AML SOUTH SAN FRANCISCO, Calif. , May 23, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced upcoming presentations from their commercial and clinical-stage hematology and oncology portfolio at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2024 Hybrid Congress.
05/10 13:01 EST - zacks.com
Rigel (RIGL) Upgraded to Buy: Here's What You Should Know
Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rigel (RIGL) Upgraded to Buy: Here's What You Should Know
Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
05/07 21:46 EST - seekingalpha.com
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2024 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel and Corporate Secretary Raul Rodriguez - President and Chief Executive Officer Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Kristen Kluska - Cantor Fitzgerald Farzin Haque - Jefferies Operator Greetings and welcome to Rigel Pharmaceuticals Financial Conference Call for the First Quarter 2024. At this time, all participants are in a listen-only mode.
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2024 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel and Corporate Secretary Raul Rodriguez - President and Chief Executive Officer Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Kristen Kluska - Cantor Fitzgerald Farzin Haque - Jefferies Operator Greetings and welcome to Rigel Pharmaceuticals Financial Conference Call for the First Quarter 2024. At this time, all participants are in a listen-only mode.
05/07 18:50 EST - zacks.com
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates
Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.08 per share a year ago.
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates
Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.08 per share a year ago.
05/07 16:01 EST - prnewswire.com
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE® net product sales of $21.1 million and REZLIDHIA ® net product sales of $4.9 million Expanded Rigel's portfolio with acquisition of GAVRETO®, a U.S. marketed product for RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Appointed Lisa Rojkjaer, M.D. as Chief Medical Officer Conference call and webcast scheduled today at 4:30 p.m.
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE® net product sales of $21.1 million and REZLIDHIA ® net product sales of $4.9 million Expanded Rigel's portfolio with acquisition of GAVRETO®, a U.S. marketed product for RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Appointed Lisa Rojkjaer, M.D. as Chief Medical Officer Conference call and webcast scheduled today at 4:30 p.m.
04/30 11:06 EST - zacks.com
Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/30 08:05 EST - prnewswire.com
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif. , April 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2024 financial results after market close on Tuesday, May 7, 2024.
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif. , April 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2024 financial results after market close on Tuesday, May 7, 2024.
04/29 07:00 EST - seekingalpha.com
Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy
Rigel Pharmaceuticals has multiple approved agents and a modest pipeline of developmental projects. The company has a stable financial position with growing sales and a new product in its stable. Rigel Pharmaceuticals faces both strengths and risks in the competitive pharmaceutical industry.
Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy
Rigel Pharmaceuticals has multiple approved agents and a modest pipeline of developmental projects. The company has a stable financial position with growing sales and a new product in its stable. Rigel Pharmaceuticals faces both strengths and risks in the competitive pharmaceutical industry.
04/10 16:30 EST - prnewswire.com
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , April 10, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , April 10, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).
04/04 08:05 EST - prnewswire.com
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Olutasidenib induced durable composite complete remission in 43.8% of patients relapsed or refractory to prior venetoclax-based regimens Safety was consistent with the overall profile of olutasidenib Olutasidenib may offer a valuable treatment option for patients with mIDH1 previously treated with venetoclax SOUTH SAN FRANCISCO, Calif. , April 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the Phase 2 study evaluating REZLIDHIA® (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1)1, in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Olutasidenib induced durable composite complete remission in 43.8% of patients relapsed or refractory to prior venetoclax-based regimens Safety was consistent with the overall profile of olutasidenib Olutasidenib may offer a valuable treatment option for patients with mIDH1 previously treated with venetoclax SOUTH SAN FRANCISCO, Calif. , April 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the Phase 2 study evaluating REZLIDHIA® (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1)1, in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.
03/12 08:05 EST - prnewswire.com
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif. , March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D.
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif. , March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D.
03/05 22:20 EST - seekingalpha.com
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2023 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q4 2023 Earnings Conference Call March 5, 2024 4:30 AM ET Company Participants Ray Furey - Executive Vice President, General Counsel and Corporate Secretary Raul Rodriguez - President and Chief Executive Officer Dave Santos - Chief Commercial Officer Francois Di Trapani - Senior Vice President of Medical Affairs Dean Schorno - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Kristen Kluska - Cantor Fitzgerald Kalpit Patel - B. Riley Securities Operator Greetings and welcome to Rigel Pharmaceuticals Financial Conference Call for the Fourth Quarter and Full Year 2023.
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2023 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q4 2023 Earnings Conference Call March 5, 2024 4:30 AM ET Company Participants Ray Furey - Executive Vice President, General Counsel and Corporate Secretary Raul Rodriguez - President and Chief Executive Officer Dave Santos - Chief Commercial Officer Francois Di Trapani - Senior Vice President of Medical Affairs Dean Schorno - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Kristen Kluska - Cantor Fitzgerald Kalpit Patel - B. Riley Securities Operator Greetings and welcome to Rigel Pharmaceuticals Financial Conference Call for the Fourth Quarter and Full Year 2023.
03/05 18:11 EST - zacks.com
Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
Rigel Pharmaceuticals (RIGL) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.
Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
Rigel Pharmaceuticals (RIGL) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.
03/05 16:01 EST - prnewswire.com
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE® net product sales of $25.7 million and REZLIDHIA ® net product sales of $3.9 million Expanded product portfolio with acquisition of U.S. rights to GAVRETO®, an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE® net product sales of $25.7 million and REZLIDHIA ® net product sales of $3.9 million Expanded product portfolio with acquisition of U.S. rights to GAVRETO®, an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.